
Selinexor Gets FDA Fast-Track Status for Penta-Refractory Myeloma Patients
Karyopharm Therapeutics recently announced that their oral drug selinexor (Selective Inhibitor of Nuclear Export) is…
Karyopharm Therapeutics recently announced that their oral drug selinexor (Selective Inhibitor of Nuclear Export) is…
At the recent American Association for Cancer Research (AACR) annual meeting in Chicago, Actinium Pharmaceuticals…
FISH testing (fluorescence in situ hybridization) is a way of testing myeloma genetics in individual…
Monday, April 16, 2018 @ 10 am Pacific, 11 am Mountain, Noon Central, 1:00 pm…
A Phase I and IIa study is open to test the safety and impact on…
Should we be screening the general population to learn more about how to prevent multiple…
Kidney issues are a common complication for multiple myeloma patients. It can be present in…
Supportive care during stem cell transplant typically includes the use of strong antibiotics like ciprofloxacin…
Viktoria Bachanova, MD, PhD University of Minnesota Interview Date: March 12, 2018 Summary Natural killer…
A new CD-38 monoclonal antibody called Isatuximab (formerly known as SAR650984) is currently in Phase…
Having myeloma and corresponding treatment can weaken the body and your ability to exercise. Difficulty with…
Treating high-risk multiple myeloma is a challenge and new drugs are being developed to address…
Inflammation that promotes tumor growth and the ability to hide from the immune system are…
Myeloma experts are learning more about the power of the CD-38 targeted monoclonal antibodies and…
Being a cancer patient is no easy task. Whether it’s financial issues, psychological burdens, or…
What is the truth regarding sugar intake as a myeloma patient? Is it okay? Should…
Monday, March 12, 2018 @ 12:30 pm Pacific, 1:30 pm Mountain, 2:30 pm Central, 3:30…
Dr. William Matsui, MD Johns Hopkins University Interview Date: February 16, 2018 Summary Allogeneic (or…
Amgen Oncology lit up the Southern California sky on Myeloma on Monday, March 5 in…
A new inhibtor (BET – Bromodomain and Extra-Terminal) is being tested in multiple myeloma. The…
Our family moved to Mexico in 2009 with the vision of helping Mexican entrepreneurs create…
Being “Patient Centric” is the buzz phrase in healthcare, but what does it actually mean?…
Bone disease is a common but challenging complication of multiple myeloma. More than 80% of…
The Dana Farber Center for Prevention of Progression of Blood Cancers study (PCrowd) for smoldering…
Juno Therapeutics today opens its Phase 1/2 study to determine the safety and efficacy of JCARH125,…
Friday, February 16, 2018 @ 11:30 am Pacific, 12:30 pm Mountain, 1:30 pm Central, 2:30…
Martin Kaiser, MD Institute of Cancer Research Interview Date: February 5, 2018 …
More treatment options are being considered for high risk smoldering multiple myeloma patients who are…
Cristina Gasparetto, MD recently shared information about a new drug combination for relapsed and refractory…
A new study has found that changes to the immune system as we age may…
Revlimid, Velcade and dexamethasone (RVd) are one of the preferred induction therapies prior to transplant.…
Myeloma Crowd Round Tables on High-Risk Disease are day-long patient education meetings featuring world class experts…
Multiple myeloma has historically not been considered an “inheritable” disease. But myeloma researchers at the…
To hear Washington University researchers speak on this topic, register for the Myeloma Crowd Round…
Dana Farber Cancer Institute myeloma specialists are studying reasons that MGUS or Smoldering Myeloma patients…
KITE Pharma, Inc. is opening a Phase I clinical trial testing its CAR T cell…
Celgene Corporation and Juno Therapeutics today announced a merger agreement in which Celgene will acquire…
Aloha to all. I live in Honolulu, HI and was diagnosed with IgG Kappa 17p…
Stem cell transplant remains the single most powerful therapy for multiple myeloma, but many patients…
Kyprolis (carfizomib) is a proteasome inhibitor that is is FDA approved to be used in…
A cellular and immune therapy company named Gamida Cell is launching a Phase I study…
Robert Z. Orlowski, MD MD Anderson Cancer Center Interview Date: January 5, 2018 Summary Much…
Most myeloma patients will receive maintenance therapy as part of their treatment plan. Data has…
The story of Immunomodulatory drugs for the treatment of multiple myeloma is one of serendipity.…
Mayo Clinic researchers have found a connection between c-reactive protein levels (a blood test marker…
Researchers at Johns Hopkins University have been studying new methods of allogeneic transplant in order…
Amgen’s new bone strengthener denosumab (XGEVA®) received FDA approval today for patients with multiple myeloma…
Myeloma Crowd Round Tables on High-Risk Disease are day-long patient education meetings featuring world class experts…
BY BRIAN HELSTIEN My parents screamed at one another right up until the divorce (when…
Revlimid, Velcade and dexamethasone (also called RVd) are considered to be an optimal treatment for…